M. Visconti

Changes in blood ROS, e-NO, and some pro-inflammatory mediators in bronchial secretions following erdosteine or placebo: A controlled study in current smokers with mild COPD

Roberto W. Dal Negro, M. Visconti, Claudio Micheletto et al. · Pulmonary Pharmacology & Therapeutics · 2007 · 48 citations

Inflammation, Inflammatory Lung Disease, Current Smokers +7

Efficacy of erdosteine 900 versus 600 mg/day in reducing oxidative stress in patients with COPD exacerbations: Results of a double blind, placebo-controlled trial

Roberto W. Dal Negro, M. Visconti, Paola Turco · Pulmonary Pharmacology & Therapeutics · 2015 · 21 citations

Allergy, Advanced Lung Disease, Pulmonary Pharmacology +7

Erdosteine affects eicosanoid production in COPD

Roberto W. Dal Negro, M. Visconti, Silvia Tognella et al. · International Journal of Clinical Pharmacology and Therapeutics · 2011 · 20 citations

Erdosteine enhances airway response to salbutamol in patients with mild-to-moderate COPD

Roberto Dal Negro, M. Visconti, Fiorenza Trevisan et al. · Therapeutic Advances in Respiratory Disease · 2008 · 14 citations · Full text

Erdosteine reduces the exercise-induced oxidative stress in patients with severe COPD: Results of a placebo-controlled trial

Roberto W. Dal Negro, M. Visconti · Pulmonary Pharmacology & Therapeutics · 2016 · 12 citations

Exercise-induced Oxidative Stress, Severe Copd, Exercise +8